Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders.
about
Aripiprazole for treating irritability in children & adolescents with autism: A systematic reviewThe association between self-injurious behaviors and autism spectrum disordersRisperidone and the 5-HT2A receptor antagonist M100907 improve probabilistic reversal learning in BTBR T + tf/J miceSubchronic treatment of donepezil rescues impaired social, hyperactive, and stereotypic behavior in valproic acid-induced animal model of autism.Lurasidone treatment in a child with autism spectrum disorder with irritability and aggression.Drug utilization in pediatric neurology outpatient department: A prospective study at a tertiary care teaching hospital.Acute Metabolic Effects of Olanzapine Depend on Dose and Injection Site.Evaluation of the Safety of Quetiapine in Treating Delirium in Critically Ill Children: A Retrospective Review.A Retrospective Naturalistic Study of Ziprasidone for Irritability in Youth with Autism Spectrum DisorderMultidisciplinary assessment and treatment of self-injurious behavior in autism spectrum disorder and intellectual disability: integration of psychological and biological theory and approach.Lurasidone for the treatment of irritability and anger in autism spectrum disorders.Second generation antipsychotics in 'real-life' paediatric patients. Adverse drug reactions and clinical outcomes of drug switch.Multiple Antipsychotic Medication Use in Autism Spectrum Disorder.Psychopharmacological prescriptions for people with autism spectrum disorder (ASD): a multinational study.Emotion regulation in children and adolescents with autism spectrum disorder.Prevalence and Predictors of Non-Suicidal Self-Injury among Children with Autism Spectrum Disorder.Autism spectrum disorders--an emerging area in psychopharmacology.17-β estradiol increases parvalbumin levels in Pvalb heterozygous mice and attenuates behavioral phenotypes with relevance to autism core symptoms.p38α MAPK signaling drives pharmacologically reversible brain and gastrointestinal phenotypes in the SERT Ala56 mouse
P2860
Q26784199-59081CE9-E2B4-4D62-86EB-16D87A429BD8Q27000448-B189B890-F83E-43B6-9EB8-20BDE1EF16E7Q28397643-FD575662-EAA9-4644-8C30-2FEF08513567Q34061622-44CC4B27-682C-44D5-A353-3A13D2AB79CFQ34063526-5F9D53B2-D087-4D6F-B46C-C73EE7B0774AQ34162563-51E109E3-764C-478E-8132-089B6971C1E7Q36371905-B8658D63-9CA8-4592-888C-EE860E1BAD99Q36730282-3C75BB77-0285-4010-803C-25DA83B50896Q37595760-168C6707-7045-40D0-968F-F8F2B7CBBF4EQ38268023-34216AF7-CF31-47F7-8EC6-76D279E431D6Q38689883-19CB318B-5860-432E-81C2-D9CA4A04D9C1Q39162868-80D214CA-A969-47BD-9B2E-E85EEBAC990EQ40433944-22B9375B-5A0D-4A19-8F35-577E1402A51FQ44569444-7C64FAE8-DCDC-4B81-841F-975B803292EBQ46854378-D7B1D859-8829-4E19-8560-8912958396A4Q47120929-8DC7097B-D446-40AA-9338-6D38922E6961Q50343855-4B275334-68E2-40EE-9C80-FD02DC6BF15CQ50418421-C2C1BB1B-B89C-46C8-BD13-A7FC07CB98D4Q57295974-78E6E2CB-9FDD-4203-9D70-49C5DE3910AD
P2860
Atypical antipsychotics in the treatment of children and adolescents with pervasive developmental disorders.
description
article científic
@ca
article scientifique
@fr
articol științific
@ro
articolo scientifico
@it
artigo científico
@gl
artigo científico
@pt
artigo científico
@pt-br
artikel ilmiah
@id
artikull shkencor
@sq
artículo científico
@es
name
Atypical antipsychotics in the ...... asive developmental disorders.
@en
type
label
Atypical antipsychotics in the ...... asive developmental disorders.
@en
prefLabel
Atypical antipsychotics in the ...... asive developmental disorders.
@en
P2860
P1433
P1476
Atypical antipsychotics in the ...... asive developmental disorders.
@en
P2093
Christopher J McDougle
Laura C Politte
P2860
P2888
P304
P356
10.1007/S00213-013-3068-Y
P577
2013-04-04T00:00:00Z
P6179
1009690486